<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36985">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02119221</url>
  </required_header>
  <id_info>
    <org_study_id>16353</org_study_id>
    <secondary_id>2013-002544-90</secondary_id>
    <nct_id>NCT02119221</nct_id>
  </id_info>
  <brief_title>Copanlisib Mass Balance Study</brief_title>
  <official_title>Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Intravenous Administration of 12 mg [14C]Copanlisib (BAY 80-6946) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to provide understanding of the relative relevance of the different excretion
      pathways of Copanlisib in humans, as well as to characterize its metabolite profile.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics of copanlisib in plasma by maximum concentration (Cmax)</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve from the first time point (t=0) extrapolated to infinity (AUC)</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve to the last data point above the lower limit of quantitation (AUC(0-tlast))</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in plasma by Cmax</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in plasma by AUC</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in plasma by AUC(0-tlast)</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in whole blood by Cmax</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in whole blood by AUC</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in whole blood by AUC(0-tlast)</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity excreted in urine as a percentage of the dose (AE,ur)</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity excreted in feces as a percentage of the dose (AE,fec)</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profile in plasma</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profile in urine</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profile in feces</measure>
    <time_frame>Multiple time points up to 336 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Until 30 days after study drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]Copanlisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib (BAY80-6946)</intervention_name>
    <description>Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of [14C]</description>
    <arm_group_label>[14C]Copanlisib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject

          -  Age: 45 to 65 years

          -  Body weight greater or equal to 60 kg and body mass index (BMI): above/equal 18 and
             below/equal 30 kg/m²

        Exclusion Criteria:

          -  Regular use of medicines

          -  Known recent (last 2 years) abuse of recreational drugs, suspicion of drug or alcohol
             abuse, or positive results of the drug and alcohol screen tests at screening or
             baseline

          -  Use of strong inhibitors of cytochrome P450 (CYP)3A4, as well as use of St John's
             Wort or strong inducers of CYP3A4 prohibited from 14 days before the administration
             of study drug until discharge from the clinic

          -  Smoking

          -  Average intake of more than 24 units of alcohol per week; Regular daily consumption
             of more than 1 L of methylxanthine-containing beverages

          -  Any condition, which may result in longer than usual retention of urine or feces in
             the body, such as pronounced (less than one defecation in 2 days) constipation or
             symptomatic prostatic hypertrophy.

          -  Participation in another mass balance study with a radiation burden &gt; 0.1 mSv in the
             period of 1 year before screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
